Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2010

View Archived Issues

First oral anaphylatoxin C5a receptor antagonist CCX-168 is safe in phase I trial

EMA orphan drug status for SBC-102 in LAL deficiency / News in Context

Preclinical studies evaluate Cz-007, Cz-008 and Cz-009 for treatment of Chagas' disease

Preclinical and first-in-human data reported on antimalarial OZ-439

ProStrakan provides update on Orexo's Abstral for cancer pain

GSK and Fiocruz expand collaboration to develop new drugs for tropical diseases

SUN-13837 accelerates functional recovery in rat models of spinal cord injury and stroke

FDA approves Vyvanse for ADHD in adolescents

Wyeth describes new PI3K-alpha/gamma and mTOR inhibitors

Isis and Xenon Pharma to develop hemojuvelin- and hepcidin-targeted drugs for anemia of inflammation

FDA grants orphan drug status to MP4CO for painful crises of sickle cell disease

Isotechnika and ILJIN to codevelop voclosporin for transplant indications

AtheroNova and Cedars-Sinai Heart Institute partner on treatment to reduce arterial plaques

Albert Einstein College of Medicine claims new Tim16 inhibitors

Infinity Pharma advances phase Ib/II IPI-926 trial in pancreatic cancer

InteRNA Technologies receives grant from Dutch government to develop miRNA-based therapeutics

Ono Pharma begins phase II trial of subcutaneous methylnaltrexone in Japan

ReNeuron treats first patient in phase I trial of ReN-001 stem cells in stroke

Lilly presents new inhibitors of 5HTT and NET

Angioblast Systems receives U.S. government grants for five stem cell projects

Janssen discloses new chemokine CCR2 receptor antagonists

Targeted Genetics enters agreement to acquire Biocontrol

Enrollment complete in ORACLE MS trial of cladribine tablets

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Phosphasgenics and 3M Pharma join to develop oxycodone pain patch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...